Daun Bahr

Title: Daun Bahr: Innovator in Psychopharmacology

Introduction

Daun Bahr is a notable inventor based in San Diego, CA, who has made significant contributions to the field of psychopharmacology. She holds a patent that addresses the treatment of psychosis through innovative drug combinations. Her work aims to enhance therapeutic outcomes while minimizing side effects.

Latest Patents

Daun Bahr's patent, titled "Combination of pimavanserin and risperidone for the treatment of psychosis," presents a novel approach to managing psychotic disorders. This patent demonstrates that combining 5-HT2A inverse agonists or antagonists, such as pimavanserin, with antipsychotics like risperidone can induce a rapid onset of antipsychotic action. The combination increases the number of responders compared to therapy with the antipsychotic alone. Furthermore, these effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective in decreasing the incidence of weight gain and elevated glucose or prolactin levels caused by the antipsychotic.

Career Highlights

Daun Bahr is currently associated with Acadia Pharmaceuticals Inc., where she continues to advance her research and development efforts. Her innovative work has positioned her as a key figure in the pharmaceutical industry, particularly in the realm of mental health treatments.

Collaborations

Throughout her career, Daun has collaborated with esteemed colleagues, including Perry Peters and David Furlano. These partnerships have fostered a collaborative environment that enhances the development of effective treatment options.

Conclusion

Daun Bahr's contributions to psychopharmacology through her patent and collaborative efforts highlight her commitment to improving mental health treatments. Her innovative approach promises to make a significant impact in the field.